opportun catch senior manag coupl time
past week nvta new cambridg facil recent
discuss singular acquisit list key question answer
continu render one top small cap pick year also preview
detail model chang begin page
background june announc enter definit merger
agreement acquir singular privat held compani develop singl molecul
detect technolog enabl lower cost expand use high-qual cell-
free nucleic acid analysi initi non-invas prenat screen nip
definit agreement acquir singular approxim subject
certain adjust mostli stock balanc cash also grant
stock award employe singular continu post-
acquisit alreadi factor addit oper expens
acquisit prior statement expect cash burn chang
manag commentari recent spoke manag singular
discuss includ eric olivar nvta head
technolog platform view singular technolog flexibl quick
less expens sequencing-bas microarray-bas approach
applic includ nips/nipt singular technolog util technolog like
mlpa multiplex ligation-depend probe amplif process two probe
design bind specif site region dna within sampl dna target
exist probe pair bind region ligat togeth short specif tag
ligat probe pair amplifi pcr quantifi indic
amount correspond dna target sampl importantli mlpa-bas
assay ostens less amplification-bia array-bas approach sinc tag
amplifi mlpa much shorter target sequenc would
amplifi array-bas approach therefor mlpa less prone error
addit singular assay far quicker microarray take
day complet hybrid technolog like abil queri
loci sampl enabl deeper profil target
applic first applic singular expect appli detect
major trisomi non-invas prenat test technolog could
broader util complementari reproduct health assay microdelet
addit manag believ singular like applic enabl
liquid biopsi specif could util low-cost monitor tool
motiv alway work find way lower cost test without
compromis qualiti point involv seek new technolog note
find way mitig cost associ nipt-ng patent pool
believ equat payment separ core cost serv
way reduc overal cost test view singular platform
time potenti allow compani gener gross margin
nipt even patient-pay rate continu page
pleas see page report import disclosur
inherit genet condit link gene variant us
market genet test estim annual expect grow
least current prohibit high cost genet test limit
incorpor routin medic practic test oncolog neurolog
pediatr price lower competitor sacrific qualiti turnaround time
recent start combimatrix acquisit expand compani menu
reproduct further mission aggreg world genet test onto
one platform futur test price reduct access improv menu expans
allow continu pick share expens specialti refer
laboratori offer singl multi-gen approach well drive broader market
adopt genet test
integr start
adopt cardiovascular test
product pipelin line
network market potenti larg
base case model
cancer test growth continu outsid
exce initi forecast
penetr larger expect
portion sizabl market opportun
genom manag genom
network servic provid new sourc
growth year
expans effort
success significantli grow
competitor respond entranc
drop price new market entrant
low price test flood market
neg revis guidelin
concern intensifi ldt regul
across pipelin product
genet inform compani process broaden offer
genet test singl servic better qualiti faster turnaround time tat
lower price single-gen diagnost test today today deliv result
genet test panel averag three week follow
result addit genet marker avail custom addit cost
day longer term plan includ progress reduc test cost lead
elast expans test volum provid servic genom manag
permission-bas genom share
step also clear technolog platform develop
requir data demonstr robust singular approach
nips/nipt need dont expect latter least
meantim continu send sampl next phase
bring nipt in-hous use sequenc third phase
would activ singular commerci platform use case
suitabl like complement ngs-nipt initi
cowen commentari impact singular alreadi captur manag
guidanc accordingli make chang model beyond year
view addit technolog potenti import step
reduc test cog includ patent fee nipt gain econom
advantag rel mani peer also possibl
import platform nvta liquid biopsi aspir cours need see data
next step might demonstr strong perform rule-out nipt
patient neg anyway reflex inconclus test
would major cost reduc
pleas note long-term dynam worth watch nipt account
sale presum larger portion ebitda doesnt seem
risk near term howev other worth watch next
year includ potenti bgi/mgi see
investor comfort volum guidanc year
background access y/i bill y/i test
growth robust lower end street expect
manag guidanc assum volum test y/i investor
concern impli ramp requir meet expect
normal cadenc histor total annual volum gener
volum account total volum impli
compani mathemat track meet full year expect
manag also indic total volum would expect
translat test consist model
commentari januari like impact time
annual sale meet week later normal march start
strong momentum volum strong end march head
april quarter particularli back-end load manag
seemingli expect manag point lower expect ratio
billable/access volum evid momentum built late
major account loss sinc quarter compani complet review
make sure noth miss conclus
account loss note account growth remain healthi may
normal week-to-week variat especi typic
newer rapidli grow salesforc
nip earli interest compani non-invas prenat screen assay
strong earli account win clearli guidanc
depend robust increas nip volum
confid would like sanguin werent momentum come
earli nip success
cowen thought manag confid compani abil meet full year
volum target notabl palpabl key pillar confid appear
histor pace build momentum account stabil earli nip win
base tone meet alon would shock came
short volum target
nip cross sell meaning mean
background key pillar logic behind move non-invas prenat
test outlook account/volum gain attribut cross sell
compani exist carrier test offer way refer
outperform nipt/carri screen cross-sel rate
carrier test cross-sel rate manag expect sell carrier
test everi nip test
oncolog test cross-sel rate manag believ sell
cancer screen everi nip test
cowen thought accord nipt complet
test reimburs elig see nip plu cross sell
lead increment volum appli follow assumpt
volum growth captur share
manag aforement cross-sel rate import context
target test volum clearli market grow quickli and/or
captur share volum contribut could much higher
background confer call manag announc plan pursu
direct channel sale strategi addit tradit sale digit
volum growth nvta us volum growth date larg driven
digit compani experi directli market
individu said hasnt made sens get aggress
menu broad enough call action
individu could besid talk physician
patient-initi activ june announc patient-initi
capabl idea individu start initi process
particularli relev reproduct health
need manag note studi indic ancestri
custom indic would interest health inform
cowen thought initi could import context longer term volum
margin target
background recent open new lab/facil cambridg primari
focu engin
artifici intellig machin learn manag indic
import close engineering/ai/ml academ hub order
attract best talent pursuant optim capabl rang bill
autom variant interpret
variant interpret amount data gener grow
exponenti includ amount phenotyp data ai/ml could also help
curat effort help genom manag clinic support
broader patient portal buildout
lower ai translat lower cost variant interpret improv
variant interpret help lower vu variant unknown
insur phenotyp necessari fulfil criteria insur
coverag effort made improv inform
guidelin phenotyp data help demonstr guidelin
cowen thought clearli want known industri
forefront innov current challeng quantifi model valu
initi pursu cambridg view effort
demonstr compani posit servic lab
background cowen confer march manag outlin goal
test asp manag back goal
recent quarterli confer call
aspir vs guidanc manag back away goal
note guidanc compani ad
test move aggress nip could drive rapid volum
growth via cross-sel assay direct channel could also drive
volum aspir could becom realiti
manag want make clear guidanc least yet
cowen thought consensu averag revenu forecast
thu appear street delin aspir guidanc
would recommend manag address topic next quarterli call
worth note current trade consensu revenu expect
discount peer extent revenu upsid even half way
aspir target share look even under-valu
look well posit meet potenti beat consensu revenu
gross margin expect
expect reiter guidanc revenu extent
manag provid commentari outlook believ indic
could consensu revenu expect slightli high
maintain revenu forecast believ potenti low
larg believ materi non-invas prenat
screen nip asp pressur like pronounc
compani like asp pressur due revenu revers
expect repeat heavi back-end load test
like lead much higher billabl test proport vs combin
like render forecast decreas asp conserv
similar logic behind view street expect gross margin could
low although recogn forecast could ultim prove
note made notabl chang structur revenu build
maintain revenu forecast explain previou section
may low
maintain total revenu forecast shift revenu
weight revenu percentag total annual revenu
slightli histor norm larg reflect assumpt
nip volum associ attach carrier screen caner panel volum
pronounc alway season stronger
 beyond modestli increas annual revenu forecast
compani achiev ebitda break-even late
stock outlook need quarter
share appreci ytd particularli notabl given share
pull back quarter appreci compani need avoid
problem came call see report result
build confid achiev target
area focu call
rebound revenu asp volum revenu forecast
volum forecast asp/test miss particularli
disappoint recent financ addit weaker expect start
year render fy target bit aspir eye mani sinc
manag exud confid fy outlook explain variou time
dynam simpli put anoth weaker expect quarter would problemat
nip outlook await detail earli ramp new account
progress addit data success cross-sel manag
assert everi nip test could drive carrier test order everi nip
test could drive cancer panel test order import context longer
term revenu margin expect
singular acquisit nip outlook june announc enter
definit merger agreement acquir singular privat held compani
develop singl molecul detect technolog enabl lower cost expand
use high-qual cell-fre nucleic acid analysi initi applic non-invas
prenat screen nip definit agreement acquir singular
approxim subject certain adjust mostli stock
balanc cash also grant stock award employe
singular continu post-acquisit
updat focus progress pharmaceut partner
potenti sourc revenu upsid time progress direct channel
maintain price target translat current revenu
forecast price/sal discount averag multipl peer group
premium peer median ghdx gh
consensu averag revenu forecast street
delin manag aspir revenu
treat guidanc would recommend manag address
topic next quarterli call
understand surfac price target seem low said
worth note current trade consensu revenu
expect discount peer extent revenu upsid even
half way manag aspir revenu target share look even
under-valu like path much closer
current trade
compani report thomson eikon cowen compani
cowen vs consensu mm except revenu guid reiter volum revenu metric mm except access forecast total total fy volum manag guidanc test growth averag revenu per billabl growth expect continu trend growth statement mm except growth per y/i nmnmnmshare count forecast revenu roughli line expect volum forecast base guidanc total fy volum alreadi volum compani guid fy volum expect asp forecast q/q decreas asp said revenu per billabl test could low one hand nip like asp headwind hand like revenu book due time process depress revenu improv test billabl continu oper improv drive gross margin forecast said given outlook nip could aggress revenu per billabl test could low one hand nip like asp headwind hand like revenu book due time process depress revenu revers made materi chang forecast technic mean consensu forecast note rang forecast adjust outlier line consensu cowen
compani report thomson eikon cowen compani
revenu guid reiter growth per cogs/test may go near term launch new productscog growth expect declin cours year gross develop base manag commentari believ could grow y/i expens grow absolut dollar growth materi y/i base manag commentari believ could grow y/i mostli oper incom interest count cagrconsensu gross oper consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit custom adopt could slower expect
continu fda uncertainti reimburs clinic guidelin hurdl low visibl
financi trajectori trade signific premium multipl
